BioTuesdays
Bioatla
Markets

HCW starts BioAtla at buy; PT $25

H.C. Wainwright launched coverage of BioAtla (NASDAQ:BCAB) with a “buy” rating and $25 price target. The stock closed at $5.77 on March 18. BioAtla is a clinical-stage biopharmaceutical company developing novel...

March 21, 2022
Talis-Logo
Markets

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

March 18, 2022
Unicycive Therapeutics
Markets

Maxim starts Unicycive Therapeutics at buy; PT $3

Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical...

March 16, 2022
Pardes Biosciences
Markets

SVB Leerink starts Pardes Biosciences at OP; PT $18

SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...

March 15, 2022
Esperion Therapeutics Logo
Markets

HCW starts Esperion at buy; PT $22

H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...

March 10, 2022
IDEAYA Biosciences Logo
Markets

Stifel ups IDEAYA Biosciences to buy; PT cut to $20

Stifel upgraded IDEAYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” but cut its price target to $20 from $27, saying the risk/reward around the company’s IDE397 drug candidate is favorable with the stock in the mid-to...

March 10, 2022
Gemini Therapeutics
Markets

SVB Leerink cuts Gemini Therapeutics to MP; PT to $2

SVB Leerink downgraded Gemini Therapeutics (NASDAQ:GMTX) to “market perform” from “outperform” and slashed its price target to $2 from $10, citing an unexpected leadership transition and corporate restructuring. The...

March 3, 2022
CTIBiopharmaLogo
Markets

Brookline ups CTI Biopharma PT to $12 from $7.20

Brookline Capital Markets raised its price target for CTI Biopharma (NASDAQ:CTIC) to $12 from $7.20 after the FDA approved Vonjo in myelofibrosis. The stock closed at $3.10, up $1.20, on volume of 108 million shares on...

March 1, 2022
Arcellx
Markets

WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...

March 1, 2022
Celyad Logo
Markets

HCW cuts Celyad Oncology to neutral; removes PT

H.C. Wainwright downgraded Celyad Oncology (NASDAQ:CYAD) to “neutral” from “buy” and removed its price target after the company paused dosing and enrollment in its Phase 1b KEYNOTE-B79 study. Shares of Celyad were...

February 28, 2022
Hepion Pharmaceuticals
Markets

Cantor starts Hepion Pharma at OW; PT $3.50

Cantor Fitzgerald launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with an “overweight” rating and $3.50 price target. The stock closed at $1.03 on Feb. 25. Hepion’s lead asset, Rencofilstat (CRV431)...

February 28, 2022
Journey Medical
Markets

Cantor starts Journey Medical at OW; PT $9

Cantor Fitzgerald initiated coverage of Journey Medical (NASDAQ:DERM) with an “overweight” rating and a 12-month price target of $9. The stock finished at $5.07 on Feb. 24. Journey is building a portfolio of commercial...

February 25, 2022
NexGel
Markets

Maxim starts NexGel at buy; PT $6

Maxim Group initiated coverage of NexGel (NASDAQ:NXGL) with a “buy” rating and a price target of $6. The stock closed at $1.81 on Feb. 24. NexGel manufactures, develops, and commercializes topical hydrogel-based...

February 25, 2022
Markets

BTIG starts Oncternal at buy; PT $5

BTIG launched coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and $5 price target. The stock closed at $1.73 on Feb. 23. Oncternal is a clinical-stage biotechnology company focused on a diverse...

February 24, 2022
Markets

Cantor starts Affimed at OW; PT $12

Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...

February 23, 2022
Zosano Logo
Markets

BTIG cuts Zosano to neutral from buy; removes PT

BTIG downgraded Zosano Pharma (NASDAQ:ZSAN) to “neutral” from “buy” and removed its price target after the FDA refused to accept the company’s NDA resubmission for M207 to treat acute migraine. Shares of Zosano, which...

February 23, 2022